Parkinson Disease — i-BiSSkApp for Swallowing Rehabilitation in Parkinson's Disease
Citation(s)
Athukorala RP, Jones RD, Sella O, Huckabee ML Skill training for swallowing rehabilitation in patients with Parkinson's disease. Arch Phys Med Rehabil. 2014 Jul;95(7):1374-82. doi: 10.1016/j.apmr.2014.03.001. Epub 2014 May 9.
Crary MA, Carnaby GD, LaGorio LA, Carvajal PJ Functional and physiological outcomes from an exercise-based dysphagia therapy: a pilot investigation of the McNeill Dysphagia Therapy Program. Arch Phys Med Rehabil. 2012 Jul;93(7):1173-8. doi: 10.1016/j.apmr.2011.11.008. Epub 2012 Feb 25.
Crary MA, Carnaby Mann GD, Groher ME, Helseth E Functional benefits of dysphagia therapy using adjunctive sEMG biofeedback. Dysphagia. 2004 Summer;19(3):160-4. doi: 10.1007/s00455-004-0003-8.
Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord. 2003 Nov;18(11):1312-6. doi: 10.1002/mds.10537.
Jenks J, Pitts LL Effects of an Intensive Exercise-Based Swallowing Program for Persons With Parkinson's Disease and Complex Medical History: A Single-Case Experiment. Am J Speech Lang Pathol. 2019 Aug 9;28(3):1268-1274. doi: 10.1044/2019_AJSLP-18-0168. Epub 2019 Jul 23.
Tabor-Gray LC, Gallestagui A, Vasilopoulos T, Plowman EK Characteristics of impaired voluntary cough function in individuals with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Feb;20(1-2):37-42. doi: 10.1080/21678421.2018.1510011. Epub 2019 Jan 17.
Troche MS, Rosenbek JC, Okun MS, Sapienza CM Detraining outcomes with expiratory muscle strength training in Parkinson disease. J Rehabil Res Dev. 2014;51(2):305-10. doi: 10.1682/JRRD.2013.05.0101.
At-Home Skill Training Using Biofeedback for Swallowing Rehabilitation in Parkinson's Disease
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
